

Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists

For Schizophrenia and Other Neuropsychiatric Disorders

Disclaimer

The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the "Company") as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third party evaluation of any securities or any offering of them and should not be considered as a recommendation that any recipient should subscribe for or purchase any securities.

The information contained herein is in summary form and does not purport to be complete. Certain information has been obtained from public sources. No representation or warranty, either express or implied, by the Company is made as to the accuracy, fairness, or completeness of the information presented herein and no reliance should be placed on the accuracy, fairness, or completeness of such information. The Company takes no responsibility or liability to update the contents of this presentation in the light of new information and/or future events. In addition, the Company may alter, modify or otherwise change in any manner the contents of this presentation, in its own discretion without the obligation to notify any person of such revision or changes.

This presentation contains "forward-looking statements," as that term is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. The words "believe", "expect", "anticipate", "intend", "plan", "seeks", "estimates", "will" and "may" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements to differ materially from those regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, change and developments in technology which may render our products obsolete, and other factors. These factors include, without limitation, those discussed in our public reports filed with the Tokyo Stock Exchange and

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Recipients of this presentation are not to construe the contents of this summary as legal, tax or investment advice and recipients should consult their own advisors in this regard.

This presentation and its contents are proprietary confidential information and may not be reproduced, published or otherwise disseminated in whole or in part without the Company's prior written consent. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This presentation contains non-GAAP financial measures. The non-GAAP financial measures contained in this presentation are not measures of financial performance calculated in accordance with IFRS and should not be considered as replacements or alternatives profit, or operating profit, as an indicator of operating performance or as replacements or alternatives to cash flow provided by operating activities or as a measure of liquidity (in each case, as determined in accordance with IFRS). Non-GAAP financial measures should be viewed in addition to, and not as a substitute for, analysis of the Company's results reported in accordance with IFRS.

References to "FY" in this presentation for periods prior to 1 January 2018 are to the 12-month periods commencing in each case on April 1 of the year indicated and ending on March 31 of the following year, and the 9 month period from April 1 2017 to December 31 2017. From January 1 2018 the Company changed its fiscal year to the 12-month period commencing in each case on January 1. References to "FY" in this presentation should be construed accordingly.

© Sosei Group Corporation. Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation. Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.



Today we are joined by Dr. Eiry Roberts, CMO at Neurocrine




DR. EIRY ROBERTS CHIEF MEDICAL OFFICER

- Appointed Chief Medical Officer in January 2018 and is responsible for all clinical development and medical affairs activities at Neurocrine.
- Over 25 years of research and development experience in the pharmaceutical industry across all phases of drug development from research through commercialization in multiple therapeutic areas, including neuroscience, inflammation, oncology and metabolic diseases.
- Joined Neurocrine from Eli Lilly and Company where she had worked since May 1991, holding various positions of increasing responsibility, including Vice President, Clinical Pharmacology/Managing Director of Chorus (October 2014 to December 2017) and Vice President of R&D, BioMedicines Business Unit.
- Trained physician in pharmacology and medicine in the UK, qualifying from the University of London in 1987. Her post-graduate clinical training was in clinical pharmacology and cardiology at St. Bartholomew's Hospital and the Royal London Hospital.
- Also serves as a director of Amicus Therapeutics, a clinical-stage biopharmaceutical company focused on rare diseases.



Announcing our up to US\$2.7 billion collaboration with Neurocrine

Developing novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric disorders



Latest major strategic partnership executed by Sosei Heptares



Neurocrine is a leading neuroscience-focused biopharmaceutical company...



- Incorporated in 1992, IPO in 1996 (Nasdaq:NBIX), with current market capitalization of ~US\$10bn
- First product approved in 2017 INGREZZA[®] (valbenazine) indicated for Tardive Dyskinesia
- Focused on discovery and development of novel therapeutics for CNS and endocrine diseases
- Headquartered in San Diego, California with approximately 900 employees



Flagship Japan-based partners of Neurocrine

- Exclusive collaboration and licensing agreement to develop and commercialize valbenazine (INGREZZA®) for movement disorders in Japan and other select Asian markets
- NBIX retained full commercial rights in North America, Europe and other countries outside of Asia

March 2015



- Strategic collaboration to develop and commercialize compounds in Takeda's early-to-mid stage psychiatry pipeline
- NBIX received exclusive license for seven Takeda pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia

June 2020



Strong history of partnering with Japan's leading science-led major pharmaceutical companies



...well-positioned for sustained and long-term growth



Strong Commercial Capabilities Experienced Sales Team 4 Approved Products* INGREZZA[®] Blockbuster Status ONGENTYS^{®⁺}Launched Q3 2020

R&D Focus on Neurological, Endocrine, and Psychiatric Disorders Robust Pipeline 12 Mid-to-Late-Stage Programs Nearly 50 Clinical Development, Health Economic and Outcomes Research Studies Underway

Strong Financial Position **Over \$1.2B Cash and Investments** (as of 30-Jun-2021) **Generating Healthy Free Cash Flow**

Neurocrine's long-term growth story to be further enhanced from its collaboration with Sosei Heptares

*AbbVie has global commercial rights to Orilissa® and Oriahnn® ⁺ Under License from BIAL

່໐ິ໑



Collaboration with Neurocrine may have a material positive financial impact on our full year FY2021 revenues

- Transaction subject to customary closing conditions, including clearance under the Hart-Scott-Rodino US Antitrust Improvements Act
- Transaction anticipated to complete by **31-Dec-2021**
 - US\$100 million upfront payment recognized as Revenue in FY2021
- Anticipated M4 Phase 2 start in 2022, plus the potential for an IND application (M1/M4 dual and/or M1 agonists) over the next 24-36 months
- Successful achievement of each development milestone event may result in the receipt of further material milestone payments


	Alliance with Neurocrine Biosciences (2021)	Former Alliance with Allergan (2016)		
Upfront License Payment	US\$100m	US\$125m		
Ongoing R&D Funding	Undisclosed	US\$55m		
Development and Regulatory Milestones	Up to US\$1.5bn	Up to US\$665m Up to US\$2.5bn		
Commercial Milestones	Up to US\$1.1bn			
Royalties	Tiered up to mid-teen % royalties	Up to double-digit tiered royalties		
Japan Territory Rights	M1 agonist for all indications	M1 agonist for Dementia with Lewy Body (DLB)		

Neurocrine is a well funded, highly motivated partner to develop the novel Muscarinic agonist programs



New collaborators value our science-led focus and proprietary insights into programs created from our StaR[®]/SBDD approach


- Portfolio of Muscarinic Agonist programs regained. Sosei Heptares conducts rapid strategic review of all preclinical and clinical data
- Sosei Heptares presents its proprietary scientific knowledge of the programs to potential partners at J.P.
 Morgan Healthcare Conference
- Sosei Heptares Board decides on targeted investment in clinical development of selected Muscarinic programs
- Sosei Heptares commences discussions with world leading neuroscience companies, including Neurocrine
- Sosei Heptares completes expansive scientific and clinical diligence process with Neurocrine
- Sosei Heptares and Neurocrine announce collaboration to develop novel muscarinic receptor agonists



Our scientific leadership and proprietary insights have enabled another exciting collaboration



Neurocrine is committed to delivering a transformative treatment for Schizophrenia with the M4 agonist HTL-0016878



The current standard of care can be improved. Selective M4 agonism represents a unique opportunity

SOSEI HEPTARES

Source: World Health Organization; EvaluatePharma

Similarly, we are committed to delivering high-quality, science-led programs for major CNS disorders under the collaboration

Preclinical	Early clinical	Late stage clinical
Sosei Heptares initially responsible for the completion of any ongoing or future preclinical activities for the M1/M4 dual and M1 agonists	Sosei Heptares may also carry out the Phase 1 clinical trials of M1/M4 dual and M1 agonists	Neurocrine will be solely responsible for all future development, regulatory and commercialization activities for M4, M1/M4 dual and M1 (ex-Japan) agonists

Neurocrine will reimburse Sosei Heptares for research activities required for an IND submission, as well as Phase 1 activities

We are initially responsible for advancing multiple earlier stage preclinical programs for novel M1/M4 dual and M1 agonists under the funded research collaboration with Neurocrine




We have retained Japan territory rights to all M1 agonists in all indications including dementia, which is a high social priority

Sosei Heptares retains the **right to develop and commercialize all M1 agonists in Japan in all indications**. Sosei Co. Ltd in Japan will be responsible for any development and commercialization of the M1 agonist programs

Neurocrine and Sosei Heptares will **share access to global safety data** and certain clinical data necessary for inclusion in regulatory filings

Neurocrine has **two opt-in triggers to co-develop and co-commercialize** the M1 assets in Japan: before commencing, and after receiving topline data from the first Phase 2 POC study Number of dementia patients in Japan set to grow as a result of a significantly ageing population



Neurocrine have the right to opt-in and co-develop and/or profit share on our Japanese M1 agonist program(s)

Source: World Health Organization, Alzheimer's International, Evaluate Pharma, Transitions in Pharmaceutical Market, Production and Sales in Japan (1980–2010), MHLW ¹ 2011 chosen as it was a peak sales year for branded donepezil in Japan. The global patent for donepezil expired in 2011.



Conclusion



Collaborating with Neurocrine – a highly motivated world-leading neuroscience-focused biopharma company and the perfect partner to advance the portfolio of potential best-in-class, selective muscarinic receptor agonists



Sosei Heptares' latest major partnership – highly attractive financial terms – US\$100m upfront and up to US\$2.6 billion in potential economics, plus tiered up to mid-teen royalties



Neurocrine anticipate initiating a Phase 2 study in 2022 for the treatment of schizophrenia with HTL-0016878, the most advanced program. Sosei Heptares to jointly advance multiple preclinical M1/M4 and M1 agonist programs



Retaining rights to develop all M1 agonists in Japan in all indications, with Neurocrine receiving co-development and profit share options

5

Significant opportunity to address high unmet medical need across major neuropsychiatric disorders

The collaboration leverages the strengths of both organisations with one goal in mind – to bring important medicines to patients who need better treatment options



Appendix

HTL-0016878 is a 4th-generation candidate aiming to be a highly effective and safer treatment for Schizophrenia

					Efficacy			Safety	
					Positive symptoms	Negative symptom	Cognitive impairment	Extrapyramidal symptoms ^{**}	Weight gain
	MoA	Typical medicine	Peak sales example	Generation	Number of patients 20M*	Number of patients 11.5M*	Number of patients 16M*	-	-
Typical antipsychotic	D2 Ant	Haldol	(Historic data unavailable)	1 st	+++	-	-	++++	+
Atypical antipsychotics	D2 Ant + 5-HT Regulator	Zyprexa Risperdal Latuda	Zyprexa \$5,000M+ (2010)	2 nd	+++	+	+	++	++++
	D2 partial Ag + 5-HT Regulator	Abilify REXULTI Vraylar	Abilify \$6,100M+ (2013)	3 rd	+++	+	+	+	+
	M4 Agonist ^{***}	KarXT CVL-231 HTL'878	-	4 th	+++	++	++	-	-

After regaining the program in early 2021, HTL-0016878 has been rapidly positioned to advance with our new partner Neurocrine

*As 1 patient can have several symptoms, number of patients in 3 symptoms is overlapping

Drug-induced movement disorders including involuntary or uncontrollable movements. tremors. muscle contractions. It is said to be related with D2 receptor occupancy balance. *Expected efficacy and expected safety derived from ongoing clinical trials of KarXT and CVL-231.



14 Source : P T. 2014 Sep; 39(9): 638–645, J Clin Psychiatry. 2010;71(3):280–286, Schizophr Bull. 2010 Jan; 36(1): 36–42 and EvaluatePharma

Neurocrine's pipeline prior to collaboration with Sosei Heptares

	PROGRAM	INDICATION	PHASE 1	PHASE 2	PHASE 3	PARTNER	2021 UPCOMING MILESTONES
Neurology	valbenazine*	Tardive Dyskinesia (Japan)	Filed Marketi	ng Authorization		Misubith Tarabe Pharma	MTPC Submitted Marketing Authorization with Ministry of Health & Welfare in Japan
	valbenazine*	Chorea in Huntington Disease	Registrationa	al			Top-Line Data Expected by Year-End
	valbenazine*	Dyskinesia Due to Cerebral Palsy	Registrationa	al			Initiating Registrational Study in 2H 2021
	NBI-827104	Rare Pediatric Epilepsy: CSWS				bdaaua	Ongoing Phase 2 Study
	NBI-827104	Essential Tremor				idorsia	Ongoing Phase 2 Study
	NBI-921352	Rare Pediatric Epilepsy: SCN8A- DEE					Initiating Phase 2 Study in 2H 2021
	NBI-921352	Focal-Onset Seizures in Adults				XENON	Initiating Phase 2 Study in 2H 2021
Endocrinology	crinecerfont	Congenital Adrenal Hyperplasia (Adults)	Registrationa	al			Ongoing Registrational Study
	crinecerfont	Congenital Adrenal Hyperplasia (Pediatric)	Registrationa	al			Ongoing Registrational Study
Psychiatry	valbenazine*	Adjunctive Treatment of Schizophrenia	Registrational				Initiating Registrational Study in 2H 2021
	luvadaxistat (NBI-1065844)	Cognitive Impairment Associated with Schizophrenia (CIAS)					Initiating Phase 2 Study in 2H 2021
	NBI-1065845	Inadequate Response to Treatment in Major Depressive Disorder					Initiating Phase 2 Study in 2H 2021
	NBI-1065846	Anhedonia in Depression					Initiating Phase 2 Study in 2H 2021

CSWS = Epileptic Encephalopathy with Continuous Spikes and Waves During Sleep Neurocrine Biosciences has global rights, unless otherwise noted. 'Mitsubishi Tanabe Pharma Corporation has commercialization rights in East Asia. Denotes program/study to be Initiated in 2021



IR@soseiheptares.com

SOSEI HEPTARES

PMO Hanzomon 11F

2-1 Kojimachi, Chiyoda-ku

Tokyo 102-0083

Japan

Steinmetz Building Granta Park, Cambridge CB21 6DG United Kingdom

North West House

119 Marylebone Road

London NW1 5PU

United Kingdom



